Showing results (31-40 of 149) with videos related to
Sort By:
Pageof 15
The Annals of Pharmacotherapy|December 1, 1996
Efficacy and safety of BMY 21,502 in Alzheimer diseaseR C Shrotriya, N R Cutler, J J Sramek, et al.Life Sciences|January 1, 1995
Safety and tolerability of CI-979 in patients with Alzheimer's diseaseJ J Sramek, A J Sedman, P A Reece, et al.Journal of Human Hypertension|November 1, 1995
Anti-hypertensive effects of intravenous compared with oral captoprilJ J Sramek, J J Brennan, D R Much, et al.The Annals of Pharmacotherapy|October 1, 1994
Safety and tolerance of intravenous nimodipineJ J Sramek, A H Heller, P R Sundaresan, et al.British Journal of Clinical Pharmacology|November 1, 1994
Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patientsR D Seifert, M B Stewart, J J Sramek, et al.Life Sciences|January 1, 1996
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseJ J Sramek, R Anand, T S Wardle, et al.Life Sciences|January 1, 1995
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesteraseJ J Sramek, G A Block, S A Reines, et al.Journal of Geriatric Psychiatry and Neurology|October 1, 1991
A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test BatteryA E Veroff, N R Cutler, J J Sramek, et al.Life Sciences|May 19, 1998
Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose studyN R Cutler, S S Jhee, P Cyrus, et al.Journal of Clinical Pharmacology|May 1, 1993
Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test batteryJ C Fleishaker, T A Sisson, J J Sramek, et al.Pageof 15